Arsanis, Inc. (ASNS) EPS Estimated At $-0.79

July 13, 2018 - By Rene Reddy

Analysts expect Arsanis, Inc. (NASDAQ:ASNS) to report $-0.79 EPS on August, 9.After having $-0.74 EPS previously, Arsanis, Inc.’s analysts see 6.76 % EPS growth. The stock decreased 2.30% or $0.08 during the last trading session, reaching $3.4. About 70,929 shares traded. Arsanis, Inc. (NASDAQ:ASNS) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody immunotherapies to address infectious diseases. The company has market cap of $48.60 million. The Company’s lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. It currently has negative earnings. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus.

More notable recent Arsanis, Inc. (NASDAQ:ASNS) news were published by: which released: “2 Healthcare Stocks Getting Buried; Option Bulls Cheer MRVL Spike” on June 28, 2018, also with their article: “Mid-Afternoon Market Update: Dow Rises Over 100 Points; Progress Software Shares Spike Higher” published on June 28, 2018, published: “Mid-Morning Market Update: Markets Edge Lower; Walgreens Beats Q3 Views” on June 28, 2018. More interesting news about Arsanis, Inc. (NASDAQ:ASNS) were released by: and their article: “Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program” published on June 14, 2018 as well as‘s news article titled: “Premarket analyst action – healthcare” with publication date: July 02, 2018.

Arsanis, Inc. (NASDAQ:ASNS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.